Key result
Adriamycin produced tumor regression in several advanced neoplastic diseases, with an overall cardiomyopathy incidence of 1.9% that increased at total doses exceeding 600 mg/m2.
Why the study?
Does doxorubicin produce tumor regression and what is its toxicity profile in patients with advanced neoplasia?
Population
485 patients (419 adults and 66 children) with various forms of advanced neoplasia treated at a single center.
Design
Case_series
Authors
Loading...
May support doxorubicin antitumor activity with cardiotoxicity monitoring; leaves open confirmation of safe dosing in randomized trials.
Observational (n=485)
No
Does doxorubicin produce tumor regression and what is its toxicity profile in patients with advanced neoplasia?
Doxorubicin is effective for various advanced neoplasms but carries a significant risk of dose-dependent cardiomyopathy, leading to the recommendation that total doses should not exceed 550 mg/m2.
Bonadonna et al. (1974) conducted an observational in Advanced Neoplasia (n=485). Adriamycin was evaluated on Tumor response and incidence of cardiomyopathy. Adriamycin produced tumor regression in several advanced neoplastic diseases, with an overall cardiomyopathy incidence of 1.9% that increased at total doses exceeding 600 mg/m2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: